Highlights & Basics
- A benign skin disease which often reflects underlying medical conditions.
- Most commonly associated with obesity and insulin resistance.
- Some cases are associated with underlying malignancy and, where no other association is identified, malignancy is investigated by complete history and examination with relevant diagnostic tests.
- Treatment of lesions is often not necessary unless they are extensive or cosmetically unacceptable and do not resolve with treatment of the underlying condition.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Citations
Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol. 1994 Jul;31(1):1-19.[Abstract]
1. Matsuoka LY, Wortsman J, Goldman J. Acanthosis nigricans. Clin Dermatol. 1993 Jan-Mar;11(1):21-5.[Abstract]
2. Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol. 1994 Jul;31(1):1-19.[Abstract]
3. Curth HO. Classification of acanthosis nigricans. Int J Dermatol. 1976 Oct;15(8):592-3.[Abstract]
4. Curth HO. Unilateral epidermal nevus resembling acanthosis nigricans. Br J Dermatol. 1976 Oct;95(4):433-6.[Abstract]
5. Berk DR, Spector EB, Bayliss SJ. Familial acanthosis nigricans due to K650T FGFR3 mutation. Arch Dermatol. 2007 Sep;143(9):1153-6.[Abstract]
6. Ersoy-Evans S, Sahin S, Mancini AJ, et al. The acanthosis nigricans form of epidermal nevus. J Am Acad Dermatol. 2006 Oct;55(4):696-8.[Abstract]
7. Brickman WJ, Binns HJ, Jovanovic BD, et al. Acanthosis nigricans: a common finding in overweight youth. Pediatr Dermatol. 2007 Nov-Dec;24(6):601-6.[Abstract]
8. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care. 2000 Mar;23(3):381-9.[Abstract][Full Text]
9. Moore RL, Devere TS. Epidermal manifestations of internal malignancy. Dermatol Clin. 2008 Jan;26(1):17-29.[Abstract]
10. Curth HO. Cancer associated with acanthosis nigricans: a review of the literature and report of a case of acanthosis nigricans with cancer of the breast. Arch Surg. 1943 Dec;47(6):517-52.
11. Schwartz RA. Acral acanthosis nigricans (acral acanthotic anomaly). J Am Acad Dermatol. 2007 Feb;56(2):349-50.[Abstract]
12. Rigel DS, Jacobs MI. Malignant acanthosis nigricans: a review. J Dermatol Surg Oncol. 1980 Nov;6(11):923-7.[Abstract]
13. Brown J, Winkelmann RK. Acanthosis nigricans: a study of 90 cases. Medicine. 1968 Jan;47(1):33-51.[Abstract]
14. Ramirez-Amador V, Esquivel-Pedraza L, Caballero-Mendoza E, et al. Oral manifestations as a hallmark of malignant acanthosis nigricans. J Oral Pathol Med. 1999 Jul;28(6):278-81.[Abstract]
15. Dyrszka H, Sanghavi B, Peddamatham K, et al. Esophageal involvement in acanthosis nigricans. NY State J Med. 1984 May;84(5):256-8.[Abstract]
16. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol. 2007 Jun;56(6):901-16.[Abstract]
17. Phiske MM. An approach to acanthosis nigricans. Indian Dermatol Online J. 2014 Jul;5(3):239-49.[Abstract][Full Text]
18. Kong AS, Williams RL, Smith M, et al. Acanthosis nigricans and diabetes risk factors: prevalence in young persons seen in southwestern US primary care practices. Ann Fam Med. 2007 May-Jun;5(3):202-8.[Abstract][Full Text]
19. Hud JA Jr, Cohen JB, Wagner JM, et al. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol. 1992 Jul;128(7):941-4.[Abstract]
20. Mukhtar Q, Cleverly G, Voorhees RE, et al. Prevalence of acanthosis nigricans and its association with hyperinsulinemia in New Mexico Adolescents. J Adolesc Health. 2001 May;28(5):372-6.[Abstract]
21. Houpt KR, Cruz PD. Acanthosis nigricans. In: Freedberg IM, Eisen AZ, Wolff K, et al, eds, Fitzpatrick's dermatology in general medicine, 6th ed. New York, NY; McGraw Hill: 2003: 1796-1801.
22. Sedano HO, Gorlin RJ. Acanthosis nigricans. Oral Surg Oral Med Oral Pathol. 1987 Apr;63(4):462-7.[Abstract]
23. Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol. 2002 Dec;147(6):1096-101.[Abstract]
24. Koyama S, Ikeda K, Sato M, et al. Transforming growth factor-alpha (TGF alpha)-producing gastric carcinoma with acanthosis nigricans: an endocrine effect of TGF alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. J Gastroenterol. 1997 Feb;32(1):71-7.[Abstract]
25. Hermanns-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol. 2004;5(3):199-203.[Abstract]
26. Schwartz RA. Acral acanthosis nigricans (acral acanthotic anomaly). J Am Acad Dermatol. 2007 Feb;56(2):349-50.[Abstract]
27. Trout CR, Levine N, Chang MW. Disorders of hyperpigmentation. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 1st ed. Edinburgh: Mosby, 2003: 1000-1001.
28. Kim YC, Davis MD, Schanbacher CF, et al. Dowling-Degos disease (reticulate pigmented anomaly of the flexures): a clinical and histopathologic study of 6 cases. J Am Acad Dermatol. 1999 Mar;40(3):462-7.[Abstract]
29. Pierson D, Bandel C, Ehrig T, et al. Benign epidermal tumors and proliferations. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 1st ed. Edinburgh: Mosby, 2003: 1717-1718.
30. Kim EJ, Lin J, Junkins-Hopkins JM, et al. Mycosis fungoides and sezary syndrome: an update. Curr Oncol Rep. 2006 Sep;8(5):376-86.[Abstract]
31. Willemze R, Scheffer E, Van Vloten WA. Mycosis fungoides simulating acanthosis nigricans. Am J Dermatopathol. 1985 Aug;7(4):367-71.[Abstract]
32. Richard G, Ringpfeil F. Ichthyoses, erythrokeratodermas and related disorders. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 1st ed. Edinburgh: Mosby, 2003: 785-786.
33. Oh JS, Kang, MS, Yu HJ, et al. Familial acanthosis nigricans showing ichthyosiform skin lesions in two sisters. J Dermatol. 2007 Sep;34(9):680-1.[Abstract]
34. Bossuyt L, Morren M, Degreef H. Transient acanthosis-nigricans-like dermatosis in re-epithelializing lesions of pemphigus foliaceus. Dermatology. 1992;185(4):309-10.[Abstract]
35. Usui K, Kondo A, Nakagawa H. Pemphigus vulgaris associated with transient acanthosis nigricans like lesion. J Dermatol. 1998 Aug;25(8):550-2.[Abstract]
36. Romo A, Benavides S. Treatment options in insulin resistance obesity-related acanthosis nigricans. Ann Pharmacother. 2008 Jul;42(7):1090-4.[Abstract]
37. Rosenbach A, Ram R. Treatment of Acanthosis nigricans of the axillae using a long-pulsed (5-msec) alexandrite laser. Dermatol Surg. 2004 Aug;30(8):1158-60.[Abstract]
38. Bredlich RO, Krahn G, Kunzi-Rapp K, et al. Continuous-wave carbon dioxide laser therapy in pseudoacanthosis nigricans. Br J Dermatol. 1998 Nov;139(5):937-8.[Abstract]
39. Wedge CC, Rootman DS, Hunter W, et al. Malignant acanthosis nigricans. A case report. Ophthalmology. 1993 Oct;100(10):1590-2.[Abstract]
40. Blobstein SH. Topical therapy with tretinoin and ammonium lactate for acanthosis nigricans associated with obesity. Cutis. 2003 Jan;71(1):33-4.[Abstract]
41. Omar HA, Logsdon S, Richards J. Clinical profiles, occurrence, and management of adolescent patients with HAIR-AN syndrome. ScientificWorldJournal. 2004 Jul 8;4:507-11.[Abstract]
42. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol. 1992 Apr;26(4):599-606.[Abstract]
43. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985 Oct 3;313(14):837-411.[Abstract]
44. National Teratology Information Service. Exposure to isotretinoin during pregnancy. Newcastle upon Tyne, England: National Teratology Information Service, Regional Drug and Therapeutics Centre, 2001.
45. Chan A, Hanna M, Abbott M, et al. Oral retinoids and pregnancy. Med J Aust. 1996 Aug 5;165(3):164-7.[Abstract]
46. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD002967.[Abstract][Full Text]
47. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015 Jan 13;58(3):429-42.[Abstract][Full Text]
48. US Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. April 2016 [internet publication].[Full Text]
